iOnctura expands clinical trial programme for NSCLC
Betsy Goodfellow | July 9, 2024 | News story | Research and Development | NSCLC, Oncology, clinical trial, iOnctura, lung cancer
iOnctura has announced the expansion of its clinical trial programme for its lead pipeline asset, roginolisib.
The drug will be assessed in combination with dostarlimab for the treatment of non-small cell lung cancer (NSCLC), through clinical collaboration agreements with the ETOP IBCSG Partners Foundation and GSK.
According to the company’s press release, ‘Roginolisib is an allosteric modulator of PI3Kδ, widely recognized as a ‘master switch’ of cancer. Inhibition of PI3Kδ unleashes a multi-pronged anti-tumour and immune response to combat the tumour. Roginolisib has demonstrated an unprecedented clinical profile in solid and liquid cancers, with 44 patients treated to date’.
Catherine Pickering, chief executive officer at iOnctura, commented: “As iOnctura moves into the next phase of clinical development, we are thrilled to be able to assess the effectiveness of roginolisib in combination with dostarlimab for the treatment of NSCLC. The successful uveal melanoma data reported so far, combined with a rich preclinical data package, support the rationale to expand our development programme with potentially synergistic combinations in NSCLC.”
Solange Peters, professor and chair of the medical oncology and thoracic malignancies programme in the department of oncology at the University Hospital of Lausanne, Switzerland, added: “On behalf of the ETOP IBCSG Partners Foundation, we are intrigued by the benefit/risk profile of roginolisib. In patients who no longer respond to current therapies, we wish to investigate whether roginolisib in combination with dostarlimab provides a novel treatment option. ETOP IBCSG Partners Foundation is committed to investigate novel treatment options to help our patients.”
Betsy Goodfellow
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
